Supreme Court rules that human genes cannot be patented (+video)
A medical breakthrough that isolates a genetic mutation does not amount to an invention meriting a patent, the US Supreme Court ruled Thursday. The decision makes it easier for researchers to engage in genetic research.
(Page 2 of 2)
Myriad applied for and received patents protecting its discovery. The company used the patents to force other researches to stop certain lines of scientific inquiry. The company also used its patents to prevent others from developing cheaper, more efficient ways to screen women for the identified genetic mutations.Skip to next paragraph
Subscribe Today to the Monitor
A group of researchers and medical patients filed a lawsuit challenging the validity of Myriad’s patents. On Thursday, they claimed victory.
“Today, the court struck down a major barrier to patient care and medical innovation,” said Sandra Park, a lawyer with the ACLU’s Women’s Rights Project. “Myriad did not invent the [mutated] genes and should not control them.”
“Because of this ruling, patients will have greater access to genetic testing and scientists can engage in research on these genes without fear of being sued [by Myriad],” Ms. Park said.
One of the plaintiffs in the case was Harry Ostrer, a genetic researcher and professor at the Albert Einstein College of Medicine at Yeshiva University in New York. He predicted the decision would expand access to genetic testing and reduce the cost of such testing.
“We will see a much more even playing field with regard to genetic testing going forward,” he said in a teleconference with reporters. “It will drive down costs and improve quality.”
Another plaintiff, breast cancer survivor Lisbeth Ceriani, said she is relieved by the ruling. “We are just glad that our genes are not being held hostage by a private corporation anymore,” she said.
Ms. Ceriani faced having to pay more than $4,000 for Myriad’s test to discover whether she carries the genetic mutation signaling a higher risk of ovarian cancer. She faced that cost because the company refused to enter into a contract with Ceriani’s insurance company.
Ceriani had to wait 18 months to get the test after receiving a grant. The test showed she does carry the mutated gene.
“I’m relieved that no other women will have to go through what I went through,” she said. “I’m so glad that the Supreme Court agrees that women deserve full access to vital information from their own bodies.”
In a statement, Myriad president and CEO Peter Meldrum focused on the portion of the ruling most favorable to Myriad.
“We believe the Court appropriately upheld our claims on cDNA, and underscored the patent eligibility of our method claims, ensuring strong intellectual property protection for our [gene mutation] test moving forward,” he said.
He noted that more than 250,000 women rely on the company’s cancer screening process each year. “We remain focused on saving and improving people’s lives and lowering overall health-care costs,” Mr. Meldrum said.
The case was Association for Molecular Pathology v. Myriad Genetics Inc. (12-398).